StockMarketWire.com - Liquid biopsy company Angle said its cell separation technology had been used in further new cancer research to highlight new areas for drug development.

Its Parsortix system was used in research, which demonstrated for the first time the role of myeloid-derived suppressor (MDSCs) cells as part of large circulating tumor cell (CTC) clusters, which were 50 times more likely to generate metastasis than single CTCs.

'This work identifies the role of immune suppressor cells within the CTC cluster highlighting key new areas for drug development with the potential for Parsortix to be routinely used as a companion diagnostic. Our ultimate aim is for the Parsortix system to be routinely used for all cancer patients in the future,' Angle said.

'ANGLE's Parsortix system has again been shown to have key advantages in harvesting CTC clusters, expanding the potential use of the Parsortix system in the growing CTC cluster research field with the prospect of routine use as a companion diagnostic for immunotherapy and other drugs to disrupt CTC clusters,' it added said.


At 9:34am: [LON:AGL] Angle PLC share price was +2.5p at 71p



Story provided by StockMarketWire.com